

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2013-01-14** | Period of Report: **2012-01-10**
SEC Accession No. [0001096906-13-000043](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

BSD MEDICAL CORP

CIK:[320174](#) | IRS No.: **751590407** | State of Incorporation: **DE** | Fiscal Year End: **0831**
Type: **8-K** | Act: **34** | File No.: [001-32526](#) | Film No.: **13527336**
SIC: **3845** Electromedical & electrotherapeutic apparatus

Mailing Address

2188 WEST
2200 SOUTH
SALT LAKE CITY UT 84119

Business Address

2188 W 2200 SOUTH
SALT LAKE CITY UT 84119
8019725555

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 10, 2013

BSD MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

0-10783

(Commission File Number)

75-1590407

(IRS Employer Identification No.)

2188 West 2200 South

Salt Lake City, Utah 84119

(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: **(801) 972-5555**

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On January 10, 2013, BSD Medical Corporation (the “Company”) issued a press release reporting financial results for its fiscal quarter ended November 30, 2012. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated January 10, 2013 regarding financial results for the fiscal quarter ended November 30, 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BSD MEDICAL
CORPORATION

Date: January 14, 2013

By: /s/ William S. Barth
Name: William S. Barth
Title: Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated January 10, 2013 regarding financial results for the fiscal quarter ended November 30, 2012

**BSD MEDICAL
CORPORATION**
2188 West 2200 South
Salt Lake City, Utah
84119-1326

Contact: Bill Barth
Telephone: (801) 972-5555
Facsimile: (801) 972-5930
Email: investor@bsdmc.com
NASDAQ:BSDM

For Immediate Release

BSD Medical Announces First Quarter Fiscal 2013 Financial Results

SALT LAKE CITY, **January 10, 2013**—BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, today reported financial results for its first fiscal quarter ended November 30, 2012, including:

- Cash and cash equivalents of \$9.1 million
- No debt
- Total stockholders' equity of \$12.6 million
- MicroThermX® revenues of \$.5 million in Q1 2013 compared to \$73,129 in Q1 2012
- Total revenues of \$659,785
- Current hyperthermia sales backlog of \$935,000
- Net loss of \$2,218,664
- Net cash used in operating activities of \$1,955,831

“Total company revenues for the quarter ended November 30, 2012 were essentially level when compared to revenues for the first quarter ended November 30, 2011. This was due primarily to a decrease in sales associated with our hyperthermia systems when comparing the two quarters. However, we recently shipped a new BSD-500 Hyperthermia System and we currently have additional sales backlog of 4 hyperthermia systems which we will deliver in fiscal 2013” said Harold Wolcott, President of the Company. “We are encouraged by the progress we have made in our MicroThermX® Microwave Ablation System (“MicroThermX®”) business. We experienced a 586% increase in sales for the MicroThermX® product line for the fiscal quarter ended November 30, 2012, as compared to the fiscal quarter ended November 30, 2011. We continue to have good working capital, no long-term debt, and we will carry on with investing in our sales and marketing and product development efforts.”

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD's product lines include both hyperthermia and ablation treatment systems. BSD's hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD's microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and well established distribution in the United States, Europe and Asia. Certain of the Company's products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

###

Forward-Looking Statements

Statements contained in this press release that are not historical facts, including statements relating to our MicroThermX® line of products, are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, including the market demand for our MicroThermX® products and the regulatory requirements we face. These forward-looking

statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.
